Abstract
Tumor vascular endothelial cells are essential constituents of the tumor microenvironment, responsible for delivering oxygen and nutrients that are vital for tumor growth and proliferation. As a hallmark of cancer progression, abnormal tumor vasculature contributes to tumor development through multiple mechanisms. Although anti-angiogenic therapies are widely used in the treatment of various cancers, the intrinsic heterogeneity of endothelial cells poses significant challenges regarding therapeutic efficacy. Therefore, further investigation into the heterogeneity of tumor endothelial cells is of paramount importance. The rapid advancement of single-cell sequencing technologies in recent years has facilitated the detailed characterization of heterogeneity among tumor endothelial cells at the single-cell level, thereby fostering a more precise understanding of the functional roles of individual cells within the tumor microenvironment. This technology has become an indispensable tool for investigating the heterogeneity of tumor endothelial cells, offering insights that could inform the refinement of future cancer treatments. In this review, we synthesize findings from the field of single-cell omics to elucidate the heterogeneous characteristics of tumor endothelial cells. We analyze recent advancements in single-cell technology used in the study of tumor cell heterogeneity in terms of both commonalities and distinctive features, covering aspects at the gene and cellular levels. In this review, we provide an overview of recent applications of single-cell sequencing technology in analyzing tumor endothelial cell heterogeneity, offering insights into the development of precise tumor therapies.
1. Introduction
As a type of stromal cell, endothelial cells constitute a critical component of the tumor microenvironment. Endothelial cells are a type of epithelial cell that form a monolayer composed of flat, polygonal cells. These cells interlock with each other, creating a continuous lining that constitutes the inner wall of blood vessels. Common marker genes for endothelial cells include KDR (Kinase Insert Domain Receptor) and CDH5 (Cadherin-5), while universal markers encompass ACKR1 (Atypical Chemokine Receptor 1), PLVAP (Plasmalemma Vesicle-Associated Protein), and IGFBP3 (Insulin-like Growth Factor Binding Protein 3). Endothelial cells play a crucial role in the secretion of vascular regulatory factors, modulation of immune responses, and tissue repair following damage, making them a vital component among the diverse cell types in the human body [1,2]. In contrast to normal endothelial cells, tumor-associated endothelial cells exhibit substantial alterations in morphology and genetics [3,4,5]. These changes encompass the formation of multi-layered endothelial structures, variations in chromosome morphology and number, and gene mutations, among other features [6,7,8]. For instance, in prostate cancer, the overall cell size and nuclear area of tumor-associated endothelial cells are significantly larger than those of normal endothelial cells [9]. These morphological and functional alterations render tumor-associated endothelial cells markedly distinct from their normal counterparts. Moreover, tumor-associated endothelial cells exhibit unique characteristics that differentiate them from normal endothelial cells. Studies have demonstrated that tumor-associated endothelial cells exhibit enhanced resistance to apoptosis and possess transcriptomic profiles that differ substantially from those of normal endothelial cells [10,11]. The tumor vasculature formed by these cells facilitates tumor progression through multiple mechanisms, including the supply of oxygen and nutrients that are essential for tumor growth [12]. Additionally, the tumor vascular system serves as a critical foundation for tumor expansion and proliferation. Research has shown that tumor-associated endothelial cells can employ metalloproteinases to degrade the vascular basement membrane [13]. Thus, in contrast to normal blood vessels, tumor-associated vessels exhibit markedly increased permeability, tortuosity, and disorganization. These structural and functional alterations promote the growth and metastasis of solid tumors, thereby constituting a critical factor contributing to tumor metastasis [14]. Moreover, recent studies have revealed that tumor vasculature not only directly supports tumor growth and metastasis but also plays a pivotal role in tumor immune evasion. Endothelial cells within the tumor microenvironment may compromise the anti-tumor immune response by modulating the infiltration of immune cells [15,16,17]. Tumor endothelial cells comprise several subpopulations that perform distinct biological functions [18]. Heterogeneity is an undeniable characteristic of these cells and presents a significant challenge in their research. Conventional biological experimental techniques are insufficient for conducting precise studies on them. In recent years, the rapid advancement of single-cell sequencing technology has enabled us to analyze the heterogeneity among tumor endothelial cells at a single-cell level. This capability allows for a more precise determination of the functions of individual cell populations within the tumor microenvironment, thereby uncovering novel therapeutic targets and identifying new treatment concepts that facilitate subsequent refined approaches to tumor therapy. The conventional pathway for single-cell sequencing is illustrated in Figure 1. However, the workflow for single-cell RNA sequencing (scRNA-seq) is often discussed in an overly idealized manner, and TEC analysis is one of the areas that is most susceptible to technical artifacts, which introduce several common challenges. Key issues include dropout events, batch effects, and low recovery rates of endothelial cells. In the context of batch effects, for instance, when identifying marker genes that distinguish endothelial cell subsets, apparent markers may instead reflect technical variation associated with batch rather than true biological differences. Furthermore, endothelial cells are typically underrepresented in final datasets due to both the difficulty of tissue dissociation and their relatively low abundance in tumor tissues. Addressing these challenges necessitates an integrated strategy spanning experimental design to data analysis, as illustrated in Figure 2.
Figure 1.
Flowchart of single-cell sequencing technology. The main steps of single-cell sequencing technology include isolating single cells, amplifying nucleic acids, performing high-throughput sequencing, and analyzing data.
Figure 2.
A comprehensive strategy for enhancing the reliability of TEC subpopulation identification in integrated single-cell datasets.
This article reviews recent advances in single-cell analysis of endothelial cells, focusing on their common features and heterogeneity across various tumor types from genetic, cellular, and therapeutic perspectives. We summarize and synthesize recent research on the heterogeneity of various tumor endothelial cells utilizing single-cell sequencing technology. This review highlights the advantages of this technology in studying tumor endothelial cells and addresses existing challenges that require resolution. Furthermore, it provides insights and directions for future research on endothelial cells across different types of tumors while anticipating potential solutions to current issues associated with single-cell sequencing technology. This review encompasses both commonalities of and distinctive characteristics inherent to tumor endothelial cells.
3. Characteristics of Tumor Endothelial Cells in Different Tumors
Different tumor endothelial cells exhibit a significant degree of intertumoral heterogeneity. This section focuses on the following three critical aspects regarding the characteristics of tumor endothelial cells: the changes in gene expression profiles compared to normal endothelial cells, the origins of tumor endothelial cells across different tumors, and targeted gene delivery therapies utilizing various vectors for endothelial targeting.
3.1. Gene Expression Changes in Tumor Endothelial Cells
Single-cell RNA sequencing (scRNA-seq) technology has revealed that TECs are not a uniform entity but rather a highly heterogeneous cell population. This heterogeneity is evident not only within the same tumor but also across different tumor types. Endothelial cells in tumors originating from different organs maintain a degree of organotypic specificity, yet they are also influenced by the tumor microenvironment (TME), acquiring distinct gene expression profiles. For example, RGCC, SPP1 (osteopontin), GPNMB, and APOE are highly expressed in hepatocellular carcinoma (HCC) [57], whereas PLVAP (PV1) [58], CD276 (B7-H3), and ESM1 are predominantly expressed in glioblastoma (GBM). Even within the same tumor, endothelial cells exhibit functional diversity: tip cells, stalk cells, and phalanx cells represent functionally distinct and heterogeneous subpopulations. Moreover, scRNA-seq has uncovered heterogeneity in cellular origin and transcriptional programs, identifying additional endothelial cell subtypes beyond the classical tip/stalk classification that often display distinct immunomodulatory functions. For instance, a subset of immunoregulatory endothelial cells (ECs) highly expresses various immune-related molecules, including PLVAP [59], CD276 (B7-H3), VCAM1, ICAM1 [60], and SELE.
TECs are a functionally diverse and highly heterogeneous population that actively participate in shaping the tumor microenvironment, rather than merely serving as passive victims. Different tumor types, such as liver cancer, brain tumors, and breast cancer, exhibit distinct endothelial cell expression profiles, suggesting that vascular-targeted therapies may need to be cancer-specific. Table 4 describes recently identified markers of endothelial cell subtypes in organ-specific cancers. Emerging therapeutic strategies are expanding beyond traditional anti-angiogenic approaches (e.g., anti-VEGF therapy) to include (a) targeting immunosuppressive endothelial cells, such as through anti-CD276 antibodies [61], to convert “cold” tumors into “hot” tumors; (b) modulating endothelial metabolism, for instance via anti-CD36 antibodies [35]; and (c) targeting specific endothelial cell subsets in distinct organs or functional states to enable more precise and effective interventions.
Table 4.
New subtypes of endothelial cells in organ-specific cancers.
3.2. Distinct Cellular Origins of Tumor Endothelial Cells
TECs originate from multiple sources, and their aberrant heterogeneity is largely attributed to this diverse cellular origin. In some tumors, the tumor endothelial cells originate from stem-cell-like endothelial cells, also referred to as endothelial progenitor cells, which are the physiological origin of endothelial cells. The tumor endothelial cells of these tumors are transformed from normal endothelial cells. In other tumors, the tumor endothelial cells are transdifferentiated from cancer cells or other cells within the tumor microenvironment, a conclusion supported by numerous pieces of evidence. For example, researchers have discovered that, in glioblastoma and lymphoma, the cytogenetic and genomic alterations of tumor endothelial cells are identical to those of cancer cells [66]. Further studies have reported that cancer cells can form pericytes, and other types of cells in the tumor microenvironment, such as dendritic cells and monocytes, also possess the ability to transdifferentiate into endothelial cells [67,68]. Hence, researchers propose that the tumor endothelial cells in these tumors are transdifferentiated from cancer cells or other cells in the tumor microenvironment.
Single-cell analysis techniques, such as scRNA-seq, can be used to infer and verify possible different origins of TECs by decoding their transcriptome signatures. Single-cell analysis tends to make inferences about where the origin is by alignment with known cell types. The core method is unsupervised clustering of scRNA-seq data (such as UMAP, t-SNE), which can identify different endothelial cell subsets. Canonical Marker Expression, Trajectory Inference, RNA Velocity, Clonality Analysis, and other methods have been used to infer EC subset origins. For example, inferred from signature gene expression, true TECs would normally express PECAM1 (CD31), CDH5 (VE-Cadherin), VWF (von Willebrand Factor), CLDN5, and so on [69,70].
Transitional tumor endothelial cells may co-express endothelial cell markers along with markers typically associated with other cell types, such as pericyte markers (e.g., PDGFRB, NG2/CSPG4) and fibroblast markers (e.g., FAP, ACTA2) [71]. This phenomenon reflects a “hybrid” transcriptomic signature. Trajectory inference algorithms, such as Monocle and PAGA, are employed to reconstruct the developmental paths of cellular transitions between distinct states. However, computational findings derived from single-cell analyses must be experimentally validated. Spatial transcriptomics and multiplex immunofluorescence (Multiplex IF) are particularly valuable for confirming the presence of cells co-expressing both endothelial and tumor-associated markers within specific spatial contexts of the tumor microenvironment, thereby validating vascular mimicry, or for identifying cells in transitional states that suggest transdifferentiation [72,73]. For example, in breast cancer, where local proliferation may represent a major aberrant origin, single-cell analysis revealed an endothelial subpopulation of cancer cells that highly expressed progenitor cell markers (CD133, KDR), and RNA velocity analysis indicated their differentiation into mature TECs [74]. In pancreatic cancer, transdifferentiation (e.g., from pericytes or fibroblasts) appears to be the primary underlying abnormal origin [33]. Single-cell analysis identified an endothelial subset co-expressing endothelial markers (CDH5) and mesenchymal markers (PDGFRB, ACTA2), and trajectory analysis revealed a continuous developmental pathway from pericytes to this endothelial subset. A study on laryngeal cancer utilized single-cell transcriptome analysis to further classify endothelial cells within laryngeal tumors into four distinct subpopulations. Among these, vascular endothelial cells characterized by FLT1 expression (vECs-FLT1) were the most abundant. Functional analyses revealed that this subpopulation was strongly associated with angiogenesis regulation, and high expression levels of the THBS1 gene in vECs-FLT1 were correlated with poorer patient prognosis. Whether tumor cells can undergo “transdifferentiation” into vascular endothelial cells has remained a subject of debate in glioblastoma (GBM) research. A study by Yan Zhou’s group at Wuhan University, combining genetic lineage tracing with copy number variation (CNV) analysis of single-cell sequencing data, demonstrated that neither vascular endothelial cells nor pericytes in GBM originate from tumor cells [75].
Single-cell analysis plays a crucial role in elucidating the origin of endothelial cells across different tumor types. On the one hand, this insight facilitates the development of novel combination therapies. For instance, if the vasculature of a particular tumor is predominantly derived from transdifferentiation, therapeutic strategies can be devised to simultaneously target both endothelial cells and their precursor cells, such as pericytes. On the other hand, tumors exhibiting a high prevalence of vascular mimicry or TECs originating from specific cell types are often associated with increased malignancy and poorer clinical outcomes. In this context, single-cell RNA sequencing (scRNA-seq) enables the identification of precise biomarkers for accurate diagnosis and prognosis. Single-cell analysis technology has revealed that tumor endothelial cells are not homogeneous but instead exhibit complex origins, well-defined differentiation trajectories, and highly specialized functional subsets. These insights not only refine and expand our understanding of the fundamental biology of tumor angiogenesis but also offer a valuable framework for overcoming resistance to anti-angiogenic therapies and guiding the development of novel combination treatment strategies.
3.3. Endothelial-Targeted Gene Delivery Therapy with Different Vectors
Endothelial-targeted gene delivery therapy is an important approach for the treatment of tumors. Due to the heterogeneity of endothelial cells across different tumor types, the optimal delivery vector varies for each tumor. For example, a novel dendritic macromolecular PAMAM-PEG-SRL nanoparticle system has demonstrated higher transfection efficiency in experiments utilizing C6 glioma cell lines, suggesting improved therapeutic efficacy [76]. Additionally, there are approaches employing poly(β-amino ester) and adeno-associated virus (AAV) for endothelial-targeted gene delivery therapy [77,78]. Different tumor endothelial cells possess distinct optimal delivery vectors tailored to their specific characteristics.
Tumor heterogeneity, vector heterogeneity, and endothelial heterogeneity are involved in the process, and single-cell analysis is currently the only technology capable of analyzing the interactions among these three components with such high resolution. In different tumor types, the key challenge lies in leveraging single-cell technology to evaluate and optimize gene delivery vectors so that they can efficiently and specifically target TECs, thereby enabling safe and effective anti-tumor therapy. Single-cell analysis is typically employed to assess the targeting efficiency of various vectors across different tumor types, and this process can be divided into four sequential stages: experimental design and preparation, in vivo delivery and sample preparation, single-cell analysis and mechanism exploration, and efficacy verification (Figure 3). By comparing the performance of different vectors in distinct tumor models, such as glioma and breast cancer, single-cell analysis enables multi-dimensional evaluation, including targeting efficiency, cell specificity, subtype preference, functional impact, and modulation of the immune microenvironment. It is important to note that, in cross-tumor comparisons, the choice of “specificity” in single-cell analysis tools directly affects the reliability of results. The primary objective of cross-tumor endothelial cell comparisons is to minimize non-biological technical variations—such as those arising from sample source and batch effects—while preserving and accurately capturing true biological differences across tumor types, subtypes, or states. For instance, in cell clustering analysis, Seurat offers distinct advantages in integration with clinical data and downstream differential expression analysis, whereas Scanpy demonstrates superior efficiency in handling ultra-large-scale datasets. Quasi-temporal analyses aim to reconstruct dynamic processes such as cell differentiation, which in cancer contexts may reflect tumor stem cell differentiation or T cell exhaustion. Monocle is designed around pseudotime inference based on cell ordering, while Slingshot emphasizes trajectory construction guided by clustering results. To define cell subtype-specific marker genes, a robust differential expression analysis framework should be employed, incorporating multiple testing correction methods such as Bonferroni or FDR. Regardless of the computational tool used, findings from cross-tumor analyses must be validated through independent experimental approaches and confirmed at the protein level using techniques such as immunohistochemistry and flow cytometry.
Figure 3.
Four sequential stages: experimental design and preparation, in vivo delivery and sample preparation, single-cell analysis and mechanism exploration, and efficacy verification.
In the future, obtaining patient samples before and after treatment for single-cell analysis will remain a major challenge in clinical practice. This may necessitate reliance on circulating endothelial cells or more sophisticated biopsy techniques. Integrating spatial transcriptomics with scRNA-seq will be essential to determine the precise localization of transfected endothelial cells within the tumor microenvironment [6,79]. The ultimate goal would be to apply single-cell technologies to characterize tumor endothelial features in individual patients, enabling the selection or design of the most suitable delivery vector to achieve true precision medicine.
4. Conclusions and Prospects
Single-cell RNA sequencing (scRNA-seq) technology is a groundbreaking tool that enables analysis of the molecular features of various cells within the tumor microenvironment (TME) at an unprecedented resolution. The heterogeneity of TECs and their complex roles in tumor progression, immune regulation, and treatment resistance are increasingly being uncovered. In this review, we summarize recent advances in scRNA-seq studies of TECs from two perspectives: commonalities and distinctive features. Specifically, TECs share certain common genes, cell subtypes, and therapeutic strategies, yet they also exhibit unique characteristics, including distinct gene expression profiles, specialized cell subtypes, and differential responses to therapies. Several functionally distinct TEC subtypes have been identified through scRNA-seq, each expressing specific marker genes and participating in diverse biological processes. For instance, in bladder cancer, a specialized endothelial cell subtype known as S1 ECs expresses the key marker gene ESM1 [80,81]. In gastric cancer, a unique endothelial cell subtype called Venes-1 is characterized by the expression of IL-33 and MADCAM1 [82,83,84].
The application of single-cell technology to study TEC usually includes the key steps of sample preparation and single-cell isolation, single-cell RNA sequencing, data analysis and cell grouping, in-depth analysis of endothelial cell subsets, and experimental verification. However, simple scRNA-seq may lose the spatial location information of cells in the original tissue. The development of spatial transcriptomics technology perfectly compensates for this deficiency. It allows us to measure gene expression while retaining spatial information on the tissue in situ. Therefore, multi-omics integration and spatial transcriptomics are important for the study of tumor endothelial cell heterogeneity. For example, in osteosarcoma studies, spatial transcriptome technology successfully captured the co-localization of MCAM+ tip-like endothelial cells in the “niche” of tumor cells in metastatic lymph nodes, explaining the metastatic propensity of tumors [30,85]. While multi-omics and spatial transcriptomics technologies advance, there are still several key challenges that significantly impact the study of tumor endothelial cells, potentially confounding the interpretation of their origin and interactions within the tumor microenvironment. For example, data alignment may be inaccurate; while single-cell sequencing enables high-resolution identification of cellular subpopulations (such as the discovery of a specialized subset of tumor endothelial cells), it lacks spatial context. In contrast, spatial transcriptomics preserve positional information but often suffer from low resolution, where a single spot can encompass multiple cells, or from limited throughput. For instance, a “pro-angiogenic endothelial cell” signature identified through scRNA-seq may appear to localize to the tumor core in spatial data. However, if data alignment is imprecise, the signal could originate from normal tissue or blood vessels in the peritumoral region at the tumor margin, potentially creating a false impression of active angiogenesis within the tumor core. Second, noise-related issues can hinder the detection of rare transcripts, particularly when key markers of endothelial cells are low-abundance molecules, thereby compromising the accuracy of cellular origin determination. Moreover, multi-omics combined with spatial data generates extremely large datasets, and the integration analysis algorithms are computationally intensive, demanding substantial computing resources and high algorithmic efficiency. For a highly heterogeneous cell type such as tumor endothelial cells, which exhibit close interactions with the surrounding microenvironment, technical and data-related noise and biases can significantly confound the interpretation of their origins and interaction networks. Acknowledging these limitations and implementing a multi-level, multi-technology validation strategy are essential for deriving robust and reliable scientific conclusions.
Currently, high-throughput single-cell capture is enabled by barcode-based technologies on next-generation sequencing platforms, allowing for the analysis of cellular heterogeneity, such as gene expression variations among distinct subsets of tumor endothelial cells and dynamic changes in cell states during development. In parallel, third-generation sequencing technologies, including PacBio and Oxford Nanopore, offer significantly longer read lengths (up to 10 kb or more), enabling more comprehensive capture of transcript structures. These capabilities make them particularly suitable for investigating complex genomic features such as gene fusions and alternative splicing events. The integration of these approaches has expanded single-cell research from mere gene expression profiling to detailed analysis of gene structure. For instance, CELLO-seq, a recently developed method, achieves high-precision mapping of transposable elements (TEs) and enables their expression and regulatory dynamics to be studied at single-cell resolution [86]. LongCell technology overcomes key challenges in alternative splicing analysis and has uncovered a novel phenomenon: intracellular splicing heterogeneity in highly expressed genes [87]. Furthermore, DeepNanoHi-C leverages deep learning models to address the sparsity and complexity inherent in single-cell 3D genomic data, thereby improving the accuracy of chromatin interaction predictions and the identification of cell-specific structural features [88]. The scMTR-seq technology developed at the University of Cambridge represents a breakthrough by enabling, for the first time, simultaneous profiling of six histone modifications and the whole transcriptome at single-cell resolution. This capability allows researchers to directly correlate epigenetic states with gene expression patterns, offering a powerful approach to uncovering the regulatory mechanisms underlying cell fate decisions [89]. To date, large-scale single-cell transcriptomic studies have independently generated pan-cancer tumor vasculature maps and endothelial cell atlases encompassing dozens of cancer types. These findings have direct clinical implications, as Zhang et al.’s analysis indicates that cancers enriched with CXCR4+ tip cells may exhibit greater sensitivity to anti-angiogenic therapies, whereas those with abundant SELE+ veins may demonstrate enhanced responsiveness to immune checkpoint inhibitors [43]. As these technologies mature and become more widely adopted, DeepNanoHi-C can be applied to investigate how alterations in 3D genome architecture regulate oncogene expression in tumor endothelial cells. Similarly, Longcell or CELLO-seq may be employed to identify critical splicing variants or transposon activation events in endothelial cells—potential candidates for therapeutic intervention. Collectively, these technological advances are elucidating the heterogeneity of tumor vascular endothelial cells with unprecedented precision and paving the way for novel therapeutic strategies.
We have discussed several technical advancements and integrations; however, with respect to the tumor itself, a diverse array of malignant cell clones coexist within the complex tumor microenvironment (TME), which comprises immune cells, stromal cells, and vascular cells. Cell-to-cell interactions, along with the availability of nutrients and oxygen, critically regulate tumor growth, differentiation, invasion, metastasis, and therapeutic response. Single-cell RNA sequencing (scRNA-seq) has uncovered a fundamental dimension of cancer biology by revealing molecular programs that integrate these multifaceted regulatory mechanisms [90]. Extracellular matrix (ECM) remodeling remains a pivotal step in tumor progression, directly influencing endothelial cell infiltration within the tumor microenvironment. Current single-cell sequencing technologies enable the investigation of key biological questions, including the mechanisms underlying ECM remodeling, newly recognized heterogeneity among endothelial cells, ECM–endothelial cell interactions, and their therapeutic implications [91]. Notably, Fan Jia’s team at Fudan University has identified two functionally opposing fibroblast subsets in hepatocellular carcinoma [92]. Meanwhile, Zhang’s research on cross-tissue multicellular coordination offers a more systematic framework, in which the concept of cell modules effectively elucidates the complexity of ECM remodeling [93]. Importantly, ECM remodeling is not merely a structural alteration but an active biological process. For instance, in gallbladder cancer, the CD34+CD90+ endothelial cell subset undergoes endothelial-to-mesenchymal transition (EndoMT) via activation of the TGF-β signaling pathway, acquiring stromal-like properties that enhance its capacity to promote tumor invasion and metastasis [65]. In early-stage gastric cancer, IL-33+ endothelial cell subsets contribute to the progression of advanced disease by upregulating adhesion molecules, enhancing angiogenesis, and facilitating mucosal infiltration. These insights have emerged from the deep integration of single-cell sequencing with multiple cutting-edge technologies, accelerating the translation of findings into clinical applications. For instance, FAP+ fibroblast signatures in renal cell carcinoma serve as potential biomarkers for predicting patient prognosis and resistance to anti-VEGF therapy [94]. By uncovering intricate interactions between the extracellular matrix (ECM) and various cell types, particularly endothelial cells, single-cell sequencing is fundamentally reshaping our understanding of tumor progression mechanisms and paving the way for novel diagnostic and therapeutic strategies.
In summary, single-cell sequencing primarily provides static snapshots of cellular states. Although promising, the application of single-cell technology in studying TECs is still hindered by several challenges. For instance, the workflow from sample preparation to data analysis requires further standardization to ensure reproducibility and comparability across studies. To better understand the dynamic changes and causal relationships in endothelial cell state transitions, it is essential to integrate complementary approaches such as organoid models, lineage tracing, and long-term functional studies. Single-cell RNA sequencing offers unprecedented insights into cellular heterogeneity and interactions [95]. In recent years, single-cell sequencing has opened a new avenue for investigating the heterogeneity of TECs, revealing that these cells are not merely passive “plumbers” but functionally diverse regulators that actively modulate the tumor immune microenvironment and influence therapeutic responses. With ongoing advances in spatial transcriptomics, multi-omics integration, and computational algorithms, such as those used to identify malignant cell populations, it is anticipated that we will be able to construct a more precise map of the tumor microenvironment. This progress may incorporate single-cell analysis into the longitudinal monitoring of patients in clinical trials [96] and ultimately enable targeted therapies directed at specific endothelial cell subtypes, thereby improving outcomes for cancer patients.
5. Literature Search
- Databases: A systematic search was conducted across several authoritative databases, including Web of Science Core Collection, Scopus, PubMed, and China National Knowledge Infrastructure (CNKI).
- Timeframe: The search covered studies published from 2010 to 2025.
- Keywords and Search String: An optimized search string was employed using a combination of subject headings and free-text words, connected by Boolean operators (AND, OR, NOT). For instance, the search string used for Web of Science was (“single cell analysis”) AND (“tumor”) AND (“endothelial cell”).
6. Literature Screening and Eligibility Criteria
Inclusion Criteria:
- (1)
- Study type: original research articles, reviews.
- (2)
- Subject: involves TECs, focuses on single-cell analysis.
- (3)
- Topic: single-cell studies of TECs.
- (4)
- Language: publications in English and Chinese.
Exclusion Criteria:
Incomplete information: articles for which the full text could not be retrieved or with insufficient data.
7. Data Analysis
We employed a thematic analysis for the final included studies. Key information, including author, publication year, study design, sample characteristics, main findings, and conclusions, was extracted from each article. This information was then inductively analyzed, compared, and synthesized to identify and distill the central themes, research trends, points of consensus, and controversies within the literature.
Author Contributions
S.L. and S.Z. wrote the manuscript. D.L. conceptualized the original idea and critically reviewed the manuscript throughout the writing and revising process. S.L. and W.S. created the figure and tables. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by the National Natural Science Foundation of China (32201225).
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
No new data were created or analyzed in this study. Data sharing is not applicable to this article.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Li, Y.; Liu, Z.; Han, X.; Liang, F.; Zhang, Q.; Huang, X.; Shi, X.; Huo, H.; Han, M.; Liu, X.; et al. Dynamics of Endothelial Cell Generation and Turnover in Arteries During Homeostasis and Diseases. Circulation 2024, 149, 135–154. [Google Scholar] [CrossRef] [Scilit]
- Meyer, A.; Zack, S.R.; Nijim, W.; Burgos, A.; Patel, V.; Zanotti, B.; Volin, M.V.; Amin, M.A.; Lewis, M.J.; Pitzalis, C.; et al. Metabolic reprogramming by Syntenin-1 directs RA FLS and endothelial cell-mediated inflammation and angiogenesis. Cell. Mol. Immunol. 2024, 21, 33–46. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bussard, K.M.; Mutkus, L.; Stumpf, K.; Gomez-Manzano, C.; Marini, F.C. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016, 18, 84. [Google Scholar] [CrossRef] [Scilit]
- Lambrechts, D.; Wauters, E.; Boeckx, B.; Aibar, S.; Nittner, D.; Burton, O.; Bassez, A.; Decaluwe, H.; Pircher, A.; Van den Eynde, K.; et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 2018, 24, 1277–1289. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Heidegger, I.; Pircher, A.; Pichler, R. Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy. Front. Oncol. 2019, 9, 490. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhong, J.; Gao, R.R.; Zhang, X.; Yang, J.X.; Liu, Y.; Ma, J.; Chen, Q. Dissecting endothelial cell heterogeneity with new tools. Cell Regen. 2025, 14, 10. [Google Scholar] [CrossRef] [Scilit]
- Cantelmo, A.R.; Conradi, L.C.; Brajic, A.; Goveia, J.; Kalucka, J.; Pircher, A.; Chaturvedi, P.; Hol, J.; Thienpont, B.; Teuwen, L.A.; et al. Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy. Cancer Cell 2016, 30, 968–985. [Google Scholar] [CrossRef] [Scilit]
- Rohlenova, K.; Veys, K.; Miranda-Santos, I.; De Bock, K.; Carmeliet, P. Endothelial Cell Metabolism in Health and Disease. Trends Cell Biol. 2018, 28, 224–236. [Google Scholar] [CrossRef] [Scilit]
- Heidegger, I.; Fotakis, G.; Offermann, A.; Goveia, J.; Daum, S.; Salcher, S.; Noureen, A.; Timmer-Bosscha, H.; Schafer, G.; Walenkamp, A.; et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol. Cancer 2022, 21, 132. [Google Scholar] [CrossRef] [Scilit]
- Agnihotri, T.G.; Salave, S.; Shinde, T.; Srikanth, I.; Gyanani, V.; Haley, J.C.; Jain, A. Understanding the role of endothelial cells in brain tumor formation and metastasis: A proposition to be explored for better therapy. J. Natl. Cancer Cent. 2023, 3, 222–235. [Google Scholar] [CrossRef] [Scilit]
- De Sanctis, F.; Ugel, S.; Facciponte, J.; Facciabene, A. The dark side of tumor-associated endothelial cells. Semin. Immunol. 2018, 35, 35–47. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Anderson, N.M.; Simon, M.C. The tumor microenvironment. Curr. Biol. 2020, 30, R921–R925. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hida, K.; Ohga, N.; Akiyama, K.; Maishi, N.; Hida, Y. Heterogeneity of tumor endothelial cells. Cancer Sci. 2013, 104, 1391–1395. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- La Porta, S.; Roth, L.; Singhal, M.; Mogler, C.; Spegg, C.; Schieb, B.; Qu, X.; Adams, R.H.; Baldwin, H.S.; Savant, S.; et al. Endothelial Tie1-mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis. J. Clin. Investig. 2018, 128, 834–845. [Google Scholar] [CrossRef] [Scilit]
- Huijbers, E.J.M.; Khan, K.A.; Kerbel, R.S.; Griffioen, A.W. Tumors resurrect an embryonic vascular program to escape immunity. Sci. Immunol. 2022, 7, eabm6388. [Google Scholar] [CrossRef] [Scilit]
- Young, M.D.; Mitchell, T.J.; Vieira Braga, F.A.; Tran, M.G.B.; Stewart, B.J.; Ferdinand, J.R.; Collord, G.; Botting, R.A.; Popescu, D.M.; Loudon, K.W.; et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 2018, 361, 594–599. [Google Scholar] [CrossRef] [Scilit]
- Dirkx, A.E.; Oude Egbrink, M.G.; Kuijpers, M.J.; van der Niet, S.T.; Heijnen, V.V.; Bouma-ter Steege, J.C.; Wagstaff, J.; Griffioen, A.W. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003, 63, 2322–2329. [Google Scholar]
- Pircher, A.; Hilbe, W.; Heidegger, I.; Drevs, J.; Tichelli, A.; Medinger, M. Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int. J. Mol. Sci. 2011, 12, 7077–7099. [Google Scholar] [CrossRef] [Scilit]
- Sievert, W.; Tapio, S.; Breuninger, S.; Gaipl, U.; Andratschke, N.; Trott, K.R.; Multhoff, G. Adhesion molecule expression and function of primary endothelial cells in benign and malignant tissues correlates with proliferation. PLoS ONE 2014, 9, e91808. [Google Scholar] [CrossRef] [Scilit]
- Hirsch, H.A.; Iliopoulos, D.; Joshi, A.; Zhang, Y.; Jaeger, S.A.; Bulyk, M.; Tsichlis, P.N.; Shirley Liu, X.; Struhl, K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010, 17, 348–361. [Google Scholar] [CrossRef] [Scilit]
- Xie, Z.; Niu, L.; Du, K.; Chen, L.; Zheng, G.; Dai, S.; Dan, H.; Duan, L.; Dou, X.; Feng, F.; et al. Endothelial cell heterogeneity in colorectal cancer: Tip cells drive angiogenesis. Cell. Mol. Life Sci. 2024, 81, 365. [Google Scholar] [CrossRef] [Scilit]
- Cervantes-Villagrana, R.D.; Albores-Garcia, D.; Cervantes-Villagrana, A.R.; Garcia-Acevez, S.J. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct. Target. Ther. 2020, 5, 99. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Taguchi, K.; Onoe, T.; Yoshida, T.; Yamashita, Y.; Tanaka, Y.; Ohdan, H. Tumor Endothelial Cell-Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway. Mol. Cancer Res. 2020, 18, 1427–1440. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bui, T.M.; Wiesolek, H.L.; Sumagin, R. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J. Leukoc. Biol. 2020, 108, 787–799. [Google Scholar] [CrossRef] [Scilit]
- Biel, N.M.; Siemann, D.W. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett. 2016, 380, 525–533. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pan, X.; Li, X.; Dong, L.; Liu, T.; Zhang, M.; Zhang, L.; Zhang, X.; Huang, L.; Shi, W.; Sun, H.; et al. Tumour vasculature at single-cell resolution. Nature 2024, 632, 429–436. [Google Scholar] [CrossRef] [Scilit]
- Zhang, J.; Lu, T.; Lu, S.; Ma, S.; Han, D.; Zhang, K.; Xu, C.; Liu, S.; Gan, L.; Wu, X.; et al. Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues. Comput. Struct. Biotechnol. J. 2023, 21, 665–676. [Google Scholar] [CrossRef] [Scilit]
- Lee, S.; Kim, H.; Kim, B.S.; Chae, S.; Jung, S.; Lee, J.S.; Yu, J.; Son, K.; Chung, M.; Kim, J.K.; et al. Angiogenesis-on-a-chip coupled with single-cell RNA sequencing reveals spatially differential activations of autophagy along angiogenic sprouts. Nat. Commun. 2024, 15, 230. [Google Scholar] [CrossRef] [Scilit]
- Funasaki, S.; Miyamura, Y.; Kamei, S.; Rahman, A.; Yamazaki, M.; Usuki, S.; Yasunaga, K.; Satou, Y.; Ohguchi, H.; Minami, T. Protocol for transcriptomic and epigenomic analyses of tip-like endothelial cells using scRNA-seq and ChIP-seq. STAR Protoc. 2025, 6, 103326. [Google Scholar] [CrossRef] [Scilit]
- Tang, H.; Cai, Y.; Yang, M.; Tang, S.; Huang, Q.; Li, H.; Liu, S.; Teng, H.; Xie, T.; He, M.; et al. Single-cell and spatial transcriptomics reveals the key role of MCAM+ tip-like endothelial cells in osteosarcoma metastasis. npj Precis. Oncol. 2025, 9, 104. [Google Scholar] [CrossRef] [Scilit]
- Pang, L.; Sun, Q.; Wang, W.; Song, M.; Wu, Y.; Shi, X.; Shi, X. A novel gene signature for predicting outcome in colorectal cancer patients based on tumor cell-endothelial cell interaction via single-cell sequencing and machine learning. Heliyon 2025, 11, e42237. [Google Scholar] [CrossRef] [Scilit]
- Rohlenova, K.; Goveia, J.; Garcia-Caballero, M.; Subramanian, A.; Kalucka, J.; Treps, L.; Falkenberg, K.D.; de Rooij, L.; Zheng, Y.; Lin, L.; et al. Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological Angiogenesis. Cell Metab. 2020, 31, 862–877.e14. [Google Scholar] [CrossRef] [Scilit]
- Parte, S.; Kaur, A.B.; Nimmakayala, R.K.; Ogunleye, A.O.; Chirravuri, R.; Vengoji, R.; Leon, F.; Nallasamy, P.; Rauth, S.; Alsafwani, Z.W.; et al. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis. Gastroenterology 2024, 166, 842–858.e5. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ye, J.; Lin, Y.; Liao, Z.; Gao, X.; Lu, C.; Lu, L.; Huang, J.; Huang, X.; Huang, S.; Yu, H.; et al. Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma. npj Precis. Oncol. 2024, 8, 262. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yue, N.; Jin, Q.; Li, C.; Zhang, L.; Cao, J.; Wu, C. CD36: A promising therapeutic target in hematologic tumors. Leuk. Lymphoma 2024, 65, 1749–1765. [Google Scholar] [CrossRef] [Scilit]
- Dejana, E.; Lampugnani, M.G. Endothelial cell transitions. Science 2018, 362, 746–747. [Google Scholar] [CrossRef] [Scilit]
- Platel, V.; Faure, S.; Corre, I.; Clere, N. Endothelial-to-Mesenchymal Transition (EndoMT): Roles in Tumorigenesis, Metastatic Extravasation and Therapy Resistance. J. Oncol. 2019, 2019, 8361945. [Google Scholar] [CrossRef] [Scilit]
- Mezyk-Kopec, R.; Potin, L.; Gomez Medellin, J.E.; Salles, C.M.; Swartz, M.A. TGF-beta Signaling Prevents MHC Class II-Expressing Lymphatic Endothelial Cells from Reactivating Human Allogenic Memory CD4+ T Cells. J. Immunol. 2023, 211, 782–790. [Google Scholar] [CrossRef] [Scilit]
- Norder, M.; Gutierrez, M.G.; Zicari, S.; Cervi, E.; Caruso, A.; Guzman, C.A. Lymph node-derived lymphatic endothelial cells express functional costimulatory molecules and impair dendritic cell-induced allogenic T-cell proliferation. FASEB J. 2012, 26, 2835–2846. [Google Scholar] [CrossRef] [Scilit]
- Wu, S.Z.; Al-Eryani, G.; Roden, D.L.; Junankar, S.; Harvey, K.; Andersson, A.; Thennavan, A.; Wang, C.; Torpy, J.R.; Bartonicek, N.; et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 2021, 53, 1334–1347. [Google Scholar] [CrossRef] [Scilit]
- Kurten, C.H.L.; Kulkarni, A.; Cillo, A.R.; Santos, P.M.; Roble, A.K.; Onkar, S.; Reeder, C.; Lang, S.; Chen, X.; Duvvuri, U.; et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat. Commun. 2021, 12, 7338. [Google Scholar] [CrossRef] [Scilit]
- Chu, X.; Li, X.; Zhang, Y.; Dang, G.; Miao, Y.; Xu, W.; Wang, J.; Zhang, Z.; Cheng, S. Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms. Nat. Cancer 2024, 5, 1409–1426. [Google Scholar] [CrossRef] [Scilit]
- Li, J.; Wang, D.; Tang, F.; Ling, X.; Zhang, W.; Zhang, Z. Pan-cancer integrative analyses dissect the remodeling of endothelial cells in human cancers. Natl. Sci. Rev. 2024, 11, nwae231. [Google Scholar] [CrossRef] [Scilit]
- Perez-Gutierrez, L.; Ferrara, N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat. Rev. Mol. Cell Biol. 2023, 24, 816–834. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- van der Meel, R.; Symons, M.H.; Kudernatsch, R.; Kok, R.J.; Schiffelers, R.M.; Storm, G.; Gallagher, W.M.; Byrne, A.T. The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. Drug Discov. Today 2011, 16, 219–228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lopes-Coelho, F.; Martins, F.; Pereira, S.A.; Serpa, J. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int. J. Mol. Sci. 2021, 22, 3765. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Walchli, T.; Ghobrial, M.; Schwab, M.; Takada, S.; Zhong, H.; Suntharalingham, S.; Vetiska, S.; Gonzalez, D.R.; Wu, R.; Rehrauer, H.; et al. Single-cell atlas of the human brain vasculature across development, adulthood and disease. Nature 2024, 632, 603–613. [Google Scholar] [CrossRef] [Scilit]
- Hosaka, K.; Andersson, P.; Wu, J.; He, X.; Du, Q.; Jing, X.; Seki, T.; Gao, J.; Zhang, Y.; Sun, X.; et al. KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas. Proc. Natl. Acad. Sci. USA 2023, 120, e2303740120. [Google Scholar] [CrossRef] [Scilit]
- Efimova, I.; Catanzaro, E.; Van der Meeren, L.; Turubanova, V.D.; Hammad, H.; Mishchenko, T.A.; Vedunova, M.V.; Fimognari, C.; Bachert, C.; Coppieters, F.; et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer 2020, 8, e001369. [Google Scholar] [CrossRef] [Scilit]
- Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23, 1011–1027. [Google Scholar] [CrossRef] [Scilit]
- Jayson, G.C.; Kerbel, R.; Ellis, L.M.; Harris, A.L. Antiangiogenic therapy in oncology: Current status and future directions. Lancet 2016, 388, 518–529. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Garcia, J.; Hurwitz, H.I.; Sandler, A.B.; Miles, D.; Coleman, R.L.; Deurloo, R.; Chinot, O.L. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 2020, 86, 102017. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yang, Y.; Zhang, Y.; Cao, Z.; Ji, H.; Yang, X.; Iwamoto, H.; Wahlberg, E.; Lanne, T.; Sun, B.; Cao, Y. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc. Natl. Acad. Sci. USA 2013, 110, 12018–12023. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cao, Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat. Rev. Endocrinol. 2014, 10, 530–539. [Google Scholar] [CrossRef] [Scilit]
- Goveia, J.; Rohlenova, K.; Taverna, F.; Treps, L.; Conradi, L.C.; Pircher, A.; Geldhof, V.; de Rooij, L.; Kalucka, J.; Sokol, L.; et al. An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. Cancer Cell 2020, 37, 421. [Google Scholar] [CrossRef] [Scilit]
- Zeng, Q.; Mousa, M.; Nadukkandy, A.S.; Franssens, L.; Alnaqbi, H.; Alshamsi, F.Y.; Safar, H.A.; Carmeliet, P. Understanding tumour endothelial cell heterogeneity and function from single-cell omics. Nat. Rev. Cancer 2023, 23, 544–564. [Google Scholar] [CrossRef] [Scilit]
- Ma, L.; Wang, L.; Khatib, S.A.; Chang, C.W.; Heinrich, S.; Dominguez, D.A.; Forgues, M.; Candia, J.; Hernandez, M.O.; Kelly, M.; et al. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Hepatol. 2021, 75, 1397–1408. [Google Scholar] [CrossRef] [Scilit]
- Liu, Y.; Carson-Walter, E.B.; Cooper, A.; Winans, B.N.; Johnson, M.D.; Walter, K.A. Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J. Neurooncol. 2010, 99, 13–24. [Google Scholar] [CrossRef] [Scilit]
- Denzer, L.; Muranyi, W.; Schroten, H.; Schwerk, C. The role of PLVAP in endothelial cells. Cell Tissue Res. 2023, 392, 393–412. [Google Scholar] [CrossRef] [Scilit]
- Singh, V.; Kaur, R.; Kumari, P.; Pasricha, C.; Singh, R. ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders. Clin. Chim. Acta 2023, 548, 117487. [Google Scholar] [CrossRef] [Scilit]
- Bejarano, L.; Kauzlaric, A.; Lamprou, E.; Lourenco, J.; Fournier, N.; Ballabio, M.; Colotti, R.; Maas, R.; Galland, S.; Massara, M.; et al. Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms. Cancer Cell 2024, 42, 378–395.e310. [Google Scholar] [CrossRef] [Scilit]
- Pu, S.; Liu, T.; Gao, Y.; Wu, Z.; Liu, S. The role of tumor-associated endothelial cells in malignant progression and immune evasion of liver cancer. Int. Immunopharmacol. 2025, 161, 115013. [Google Scholar] [CrossRef] [Scilit]
- Sun, X.; Cai, W.; Li, H.; Gao, C.; Ma, X.; Guo, Y.; Fu, D.; Xiao, D.; Zhang, Z.; Wang, Y.; et al. Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling. Gut 2025, 74, 1437–1451. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhou, L.; Yang, M.; Deng, C.; Hu, M.; Wu, S.; Lai, K.; Zhang, L.; Chen, Z.; Tang, Q.; Wang, Q.; et al. Single-cell sequencing reveals the role of IL-33+ endothelial subsets in promoting early gastric cancer progression. iMeta 2025, 4, e70050. [Google Scholar] [CrossRef] [Scilit]
- Hou, M.; Chen, J.; Jiang, Y.; Liu, C.; Wang, X.; Liu, E.; Zong, Y.; Gu, M.; Meng, Z.; Wang, S.; et al. Single-cell analysis reveals CD34+CD90+ endothelial cells promote tumor metastasis in gallbladder cancer. npj Precis. Oncol. 2025, 9, 242. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, H.; Guo, C.; Wang, C.; Xu, J.; Zheng, S.; Duan, J.; Li, Y.; Bai, H.; Xu, Q.; Ning, F.; et al. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. Cancer Sci. 2023, 114, 2609–2621. [Google Scholar] [CrossRef] [Scilit]
- Bosisio, D.; Ronca, R.; Salvi, V.; Presta, M.; Sozzani, S. Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. Curr. Opin. Immunol. 2018, 53, 180–186. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Havemann, K.; Pujol, B.F.; Adamkiewicz, J. In vitro transformation of monocytes and dendritic cells into endothelial like cells. Adv. Exp. Med. Biol. 2003, 522, 47–57. [Google Scholar]
- Yang, R.; Zhou, Y.; Du, C.; Wu, Y. Bioinformatics analysis of differentially expressed genes in tumor and paracancerous tissues of patients with lung adenocarcinoma. J. Thorac. Dis. 2020, 12, 7355–7364. [Google Scholar] [CrossRef] [Scilit]
- Danoy, M.; Jellali, R.; Tauran, Y.; Bruce, J.; Leduc, M.; Gilard, F.; Gakiere, B.; Scheidecker, B.; Kido, T.; Miyajima, A.; et al. Characterization of the proteome and metabolome of human liver sinusoidal endothelial-like cells derived from induced pluripotent stem cells. Differentiation 2021, 120, 28–35. [Google Scholar] [CrossRef] [Scilit]
- Jiang, Z.; Zhou, J.; Li, L.; Liao, S.; He, J.; Zhou, S.; Zhou, Y. Pericytes in the tumor microenvironment. Cancer Lett. 2023, 556, 216074. [Google Scholar] [CrossRef] [Scilit]
- Ou, Z.; Lin, S.; Qiu, J.; Ding, W.; Ren, P.; Chen, D.; Wang, J.; Tong, Y.; Wu, D.; Chen, A.; et al. Single-Nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological Microenvironment of Cervical Squamous Cell Carcinoma. Adv. Sci. 2022, 9, e2203040. [Google Scholar] [CrossRef] [Scilit]
- Peng, H.; Wu, X.; Liu, S.; He, M.; Xie, C.; Zhong, R.; Liu, J.; Tang, C.; Li, C.; Xiong, S.; et al. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment. Clin. Transl. Med. 2023, 13, e1155. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mugisha, S.; Labhsetwar, S.; Dave, D.; Klemke, R.; Desgrosellier, J.S. A dataset of chronic nicotine-induced genes in breast cancer cells. Data Brief. 2025, 60, 111573. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, F.; Liu, X.; Li, S.; Zhao, C.; Sun, Y.; Tian, K.; Wang, J.; Li, W.; Xu, L.; Jing, J.; et al. Resolving the lineage relationship between malignant cells and vascular cells in glioblastomas. Protein Cell 2023, 14, 105–122. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zarebkohan, A.; Najafi, F.; Moghimi, H.R.; Hemmati, M.; Deevband, M.R.; Kazemi, B. SRL-Coated PAMAM Dendrimer Nano-Carrier for Targeted Gene Delivery to the Glioma Cells and Competitive Inhibition by Lactoferrin. Iran. J. Pharm. Res. 2016, 15, 629–640. [Google Scholar]
- Wu, G.; Jiang, Q.; Cui, T.; Liu, X.; Gong, D.; Yin, Y.; Wang, C.; Wang, T.; Lu, Y.; Zhu, D.; et al. The glymphatic system delivery enhances the transduction efficiency of AAV1 to brain endothelial cells in adult mice. J. Neurosci. Methods 2019, 328, 108441. [Google Scholar] [CrossRef] [Scilit]
- Barbon, E.; Kawecki, C.; Marmier, S.; Sakkal, A.; Collaud, F.; Charles, S.; Ronzitti, G.; Casari, C.; Christophe, O.D.; Denis, C.V.; et al. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Ther. 2023, 30, 245–254. [Google Scholar] [CrossRef] [Scilit]
- Wen, Y.; Ju, C. New insights into liver injury and regeneration from single-cell transcriptomics. eGastroenterology 2025, 3, e100202. [Google Scholar] [CrossRef] [Scilit]
- Qiu, Y.; Wang, Y.; Liu, J.; Liu, B.; Sun, K.; Hou, Q. Single-cell sequencing uncovers a high ESM1-expression endothelial cell subpopulation associated with bladder cancer progression and the immunosuppressive microenvironment. Sci. Rep. 2025, 15, 10946. [Google Scholar] [CrossRef] [Scilit]
- Xu, W.; Liang, T.; Fang, H.; Fu, L.; Deng, D.; Tan, X.; Liu, L.; Tang, D.; Zheng, H.; Ding, Q.; et al. Single-Cell RNA Sequencing Identifies MMP11+ Cancer-Associated Fibroblasts as Drivers of Angiogenesis and Bladder Cancer Progression. Adv. Sci. 2025, 12, e02774. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kumar, V.; Ramnarayanan, K.; Sundar, R.; Padmanabhan, N.; Srivastava, S.; Koiwa, M.; Yasuda, T.; Koh, V.; Huang, K.K.; Tay, S.T.; et al. Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer. Cancer Discov. 2022, 12, 670–691. [Google Scholar] [CrossRef] [Scilit]
- Zhang, P.; Yang, M.; Zhang, Y.; Xiao, S.; Lai, X.; Tan, A.; Du, S.; Li, S. Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer. Cell Rep. 2019, 27, 1934–1947.e1935. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, M.; Hu, S.; Min, M.; Ni, Y.; Lu, Z.; Sun, X.; Wu, J.; Liu, B.; Ying, X.; Liu, Y. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut 2021, 70, 464–475. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, Y.; He, M.; Tang, H.; Xie, T.; Lin, Y.; Liu, S.; Liang, J.; Li, F.; Luo, K.; Yang, M.; et al. Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma. BMC Med. 2024, 22, 200. [Google Scholar] [CrossRef] [Scilit]
- Marlow, S.A.; Deaville, L.A.; Berrens, R.V. Long-read RNA sequencing of transposable elements from single cells using CELLO-seq. Nat. Protoc. 2025, 20, 3070–3095. [Google Scholar] [CrossRef] [Scilit]
- Fu, Y.; Kim, H.; Adams, J.I.; Grimes, S.M.; Huang, S.; Lau, B.T.; Sathe, A.; Hess, P.; Ji, H.P.; Zhang, N.R. Single cell and spatial alternative splicing analysis with long read sequencing. Res Sq. 2023. [Google Scholar] [CrossRef] [Scilit]
- Ma, W.; Wang, F.; Fan, Y.; Hao, G.; Su, Y.; Wong, K.C.; Li, X. DeepNanoHi-C: Deep learning enables accurate single-cell nanopore long-read data analysis and 3D genome interpretation. Nucleic Acids Res. 2025, 53, gkaf640. [Google Scholar] [CrossRef] [Scilit]
- Wang, Y.; Li, J.; Malcolm, A.A.; Mansfield, W.; Clark, S.J.; Argelaguet, R.; Biggins, L.; Acton, R.J.; Andrews, S.; Reik, W.; et al. Combinatorial profiling of multiple histone modifications and transcriptome in single cells using scMTR-seq. Sci. Adv. 2025, 11, eadu3308. [Google Scholar] [CrossRef] [Scilit]
- Tirosh, I.; Suva, M.L. Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors. Cancer Cell 2024, 42, 1497–1506. [Google Scholar] [CrossRef] [Scilit]
- Lavie, D.; Ben-Shmuel, A.; Erez, N.; Scherz-Shouval, R. Cancer-associated fibroblasts in the single-cell era. Nat. Cancer 2022, 3, 793–807. [Google Scholar] [CrossRef] [Scilit]
- Cheng, Y.; Chen, X.; Feng, L.; Yang, Z.; Xiao, L.; Xiang, B.; Wang, X.; Liu, D.; Lin, P.; Shi, J.; et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma. Cell Discov. 2025, 11, 1. [Google Scholar] [CrossRef] [Scilit]
- Shi, Q.; Chen, Y.; Li, Y.; Qin, S.; Yang, Y.; Gao, Y.; Zhu, L.; Wang, D.; Zhang, Z. Cross-tissue multicellular coordination and its rewiring in cancer. Nature 2025, 643, 529–538. [Google Scholar] [CrossRef] [Scilit]
- Ma, J.; Huang, Y.; Chen, J.; Li, Y.; Yao, R.; Li, X.; Liang, Q.; Chen, X.; Peng, C.; Liu, K.; et al. FAP+ fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus. Nat. Commun. 2025, 16, 9387. [Google Scholar] [CrossRef] [Scilit]
- Yang, S.; Deng, C.; Pu, C.; Bai, X.; Tian, C.; Chang, M.; Feng, M. Single-Cell RNA Sequencing and Its Applications in Pituitary Research. Neuroendocrinology 2024, 114, 875–893. [Google Scholar] [CrossRef] [Scilit]
- Han, J.; DePinho, R.A.; Maitra, A. Single-cell RNA sequencing in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 451–452. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).


